Sun Pharma posts Q2 profit of ₹1,064 cr
NEW DELHI: Sun Pharmaceutical Industries Ltd on Thursday reported a consolidated net profit of ₹1,064.09 crore in the second quarter ended September 30.
The company had posted a consolidated net loss of ₹269.6 crore in the same period last fiscal, Sun Pharma said in a regulatory filing.
Total revenue from operations during the period under review stood at ₹8,123.35 crore as against ₹6,937.63 crore in the year-ago quarter, it added.
During the quarter, India sales were at ₹2,515 crore, growth of 35% over the second quarter last year, while the US finished dossavings age sales were at $339 million flat over the same period last year, the company said.
The sales in emerging markets were at $201 million, up by 3% and that of the rest of world were at $161 million, a growth of 49%.
Commenting on the financial performance, Sun Pharma managing director Dilip Shanghvi said it demonstrates sustained growth momentum of the company.
“We continue to focus on cost and efficiency improvement to align our generic business with the changing industry dynamics. Simultaneously, we continue to progress on building our global specialty business,” he added.
Sun Pharma said its active pharmaceutical ingredients clocked external sales of ₹468 crore, up 10% over the same quarter last fiscal.
The company said its consolidated research and development investment for the second quarter was ₹488 crore, which was 6.1% of sales as compared to ₹452 crore (6.6% of sales in the yearago quarter). Shares of Sun Pharmaceutical Industries closed at ₹440.45 apiece on BSE, up 3.02% from the previous close.